Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1990-12-26
1994-02-08
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514261, 514262, 514263, 544244, 544264, 544265, 544267, 544271, 544272, 544276, 544277, C07D47318, C07D47332, C07D47334, A61K 3152
Patent
active
052848370
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to novel and known chemical compounds and pharmaceutically acceptable salts thereof for use in therapy for therapeutic and prophylactic treatment of the acquired immuno deficiency syndrome (AIDS) and infections caused by viruses requiring reverse transcriptase for replication, such as human immunodeficiency viruses and hepatitis B viruses, and also for treatment of other virus disease, such as those of herpes viruses, diseases which include both common infections and neoplastic disease, i.e. cancer.
BACKGROUND OF THE INVENTION
The effects of viruses on bodily functions is the end result of changes occurring at the cellular and subcelluar levels. The pathogenic changes at the cellular level are different for different combinations of viruses and host cells. While some viruses cause a general destruction (killing) of certain cells, other may transform cells into a neoplastic state.
Important common viral infections are herpes dermatitis (including herpes labialis), herpes keratitis, herpes genitalis, herpes zoster, herpes encephalitis, infectious mononucleosis and cytomegalovirus infections all of which are caused by viruses belonging to the herpes virus group. Other important viral diseases are influenza A and B which are caused by influenza A and B virus respectively. Another important common viral disease is viral hepatitis and especially hepatitis B virus infections are widely spread. Effective and selective antiviral agents are needed for treatment of these diseases as well as for other diseases caused by viruses.
Several different viruses of both DNA and RNA type have been shown to cause tumors in animals. The effect of cancerogenic chemicals can on animals result in activation of latent tumor viruses. It is possible that tumor viruses are involved in human tumors. The most likely human cases shown today are leukemias, sarcomas, breast carcinomas, Burkitt lymphomas, nasopharyngeal carcinomas and cervical cancers where RNA tumor viruses and herpes viruses are indicated. This makes the search for selective inhibitors of tumorogenic viruses and their functions an important undertaking in the efforts to treat cancer.
In the late seventies a new disease was reported, which subseqently was referred to as Acquired Immuno Deficiency Syndrome (AIDS). It is now generally accepted that a retrovirus referred to as HIV (Human Immunodeficiency Virus), formerly known as Human T-cell Lymphotropic Virus (HTLV-III) or Lymphadenopathy Associate Virus (LAV) plays an essential role in the etiology of AIDS. Different types of HIV have been found such as HIV-1 and HIV-2 and more are likely to be isolated.
AIDS is characterized by a profound immunodeficiency due to low numbers of a subset of lymphocyte-T-helper cells, which are one target for HIV-infection. The profound immunodeficiency in AIDS patients makes these patients highly susceptible to a variety of opportunistic infections of bacterial, fungal protozoal or viral etiology. The etiological agents among viral opportunistic infections are often found in the herpes virus group, i.e. herpes simplex virus (HSV), Varicella Zoster virus (VZV), Epstein-Barr Virus (EBV) and, especially, cytomegalovirus (CMV). Other retroviruses affecting animals are feline leukemia virus and equine infectious anaemia virus. Human diseases such as multiple sclerosis, psoriasis and Kawasaki disease have also been reported to be associated with retrovirus infections.
Hepatitis B virus infections cause severe disease such as acute hepatitis, chronic hepatitis, fulminant hepatitis in a considerable number of persons. It is estimate that there are 200 million patients with chronic hepatitis B infection in the world. A considerably number of the chronic cases progress to liver cirrosis and liver tumours. In some cases the hepatitis infections also take a rapid and severe course as in fulminant B hepatitis with about 90% mortality. At present there is no known effective treatment against hepatitis B infections. The replication of hepatitis B vir
REFERENCES:
patent: 4199574 (1980-04-01), Schaeffer
patent: 4565868 (1986-01-01), Verheyden et al.
patent: 4590269 (1986-05-01), Prisbe et al.
patent: 4714701 (1987-12-01), Beauchamp
Lundgren, J. Acquired Immun. Def. Syndromes 4, 489-498 (1991).
Wyand, AIDS Research and Human Retroviruses 8, 349 (1992).
Martin et al., Antiviral Research 1990, 1 (Suppl) 114.
Wahrtn, Antimicrob. Agents & Chemotherapy 32(8), pp. 1137-1142 (1988).
Larsson et al, Antimicrobial Agents and Chemotherapy, vol. 30, No. 4, pp. 598-605 (1986).
Abele et al, Antimicrobial Agents and Chemotherapy, vol. 31, No. 1, pp. 76-80 (1987).
berg Bo F.
Datema Roelf
Johansson Karl N. G.
Lindborg Bjorn G.
Berch Mark L.
Medivir AB
LandOfFree
Derivatives of purine, process for their preparation and a pharm does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of purine, process for their preparation and a pharm, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of purine, process for their preparation and a pharm will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-697988